Grace Therapeutics, Inc. (GRCE)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 03-31. Amounts in USD.

Revenue Quarterly

0 40K 80K 120K Q3 '21: 81K Q4 '21: 115K Q3 '22: 0 Q4 '22: 0 Q3 '21 Q4 '21 Q3 '22 Q4 '22

Gross Profit Quarterly

0 30K 60K 90K Q3 '21: 45K Q4 '21: 75K Q3 '22: 0 Q4 '22: 0 Q3 '21 Q4 '21 Q3 '22 Q4 '22

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-18M -12M -6M 0 6M 12M 18M Q2 '25: -4.8M Q3 '25: -3.7M Q4 '25: -3.2M Q1 '26: -3.1M Q2 '26: -2.5M Q3 '26: -2.4M Q4 '26: -3M Q1 '27: -15.9M Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26 Q3 '26 Q4 '26 Q1 '27

Net Income Quarterly

-18M -12M -6M 0 6M 12M 18M Q2 '25: -3.4M Q3 '25: -4.2M Q4 '25: 636K Q1 '26: -3.4M Q2 '26: -938K Q3 '26: -2.3M Q4 '26: -1.2M Q1 '27: -15.8M Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26 Q3 '26 Q4 '26 Q1 '27

Cost of Revenue Quarterly

0 15K 30K 45K Q3 '21: 36K Q4 '21: 40K Q3 '22: 0 Q4 '22: 0 Q3 '21 Q4 '21 Q3 '22 Q4 '22

Operating Cash Flow Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q2 '25: -4.2M Q3 '25: -4.1M Q4 '25: -3M Q1 '26: -1.8M Q2 '26: -3.1M Q3 '26: -2.2M Q4 '26: -1.7M Q1 '27: -3.2M Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26 Q3 '26 Q4 '26 Q1 '27

Free Cash Flow Quarterly

-27M -18M -9M 0 9M 18M 27M Q4 '19: -25.3M Q1 '20: -6.8M Q4 '20: -23.3M Q1 '21: -4.2M Q4 '19 Q1 '20 Q4 '20 Q1 '21

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 6M 12M 18M Q3 '24: 11.5M Q1 '25: 10.9M Q2 '25: 11.5M Q3 '25: 11.5M Q1 '26: 15.9M Q2 '26: 15.9M Q3 '26: 16.9M Q1 '27: 17.3M Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26 Q3 '26 Q1 '27

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.20 -0.80 -0.40 0.00 0.40 0.80 1.20 Q2 '25: -1.01 Q3 '25: -1.16 Q4 '25: -0.79 Q1 '26: -0.76 Q2 '26: -0.52 Q3 '26: -0.30 Q4 '26: -0.47 Q1 '27: -1.17 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26 Q3 '26 Q4 '26 Q1 '27

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.